section name header

Pronunciation

eye-VAB-ra-deen

Classifications

Therapeutic Classification: heart failure agents

Pharmacologic Classification: hyperpolarization-activated cyclic nucleotide-gated channel blockers

Indications

REMS


Action

  • Inhibits the cardiac pacemaker If-current by acting as a hyperpolarization-activated cyclic nucleoside-gated channel blocker, resulting in spontaneous pacemaker activity of sinus node. Decreases heart rate without affecting contractility or ventricular repolarization.
Therapeutic effects:
  • Lowering of heart rate with reduced need for hospitalization in patients with HF.

Pharmacokinetics

Absorption: 40% absorbed following oral administration (undergoes first pass metabolism); food delays absorption and blood levels.

Distribution: Unknown.

Metabolism/Excretion: Extensively metabolized, primarily by the CYP3A4 enzyme system. The major metabolite is pharmacologically active and has the same potency as ivabradine. Metabolites excreted equally in urine and feces; 4% excreted unchanged in urine.

Half-Life: 6 hr.

Time/Action Profile

(blood levels)

ROUTEONSETPEAKDURATION
POunknown1 hr12 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: atrial fibrillation, bradycardia, heart block, hypertension, QT interval prolongation, sinus arrest, TORSADES DE POINTES

EENT: phosphenes (luminous phenomena)

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Availability

(Generic available)

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Corlanor

Canadian Brand Names

Lancora